You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Sensitivity Analysis Methods for Complex, Multidisciplinary Systems

    SBC: SCIENTIFIC SIMULATIONS, LLC            Topic: AF11BT06

    ABSTRACT: The objective of this proposal is to develop efficient sensitivity analysis methods based on adjoint techniques for multi-disciplinary time-dependent problems. The approach is based on the discrete adjoint, which is derived and implemented on a software component basis, with the various multidisciplinary software components being linked together through a Python interface, thus preservi ...

    STTR Phase II 2014 Department of DefenseAir Force
  2. Real-time bioimpedance based biopsy device

    SBC: RYTEK MEDICAL INC            Topic: NCI

    DESCRIPTION (provided by applicant): Over the last three decades the number of men diagnosed with prostate cancer has increased 85% as a result of new screening and diagnostic tools. However, a significant number of these newly diagnosed men are harboringclinically insignificant disease, which means that they are not likely to die from prostate cancer. A difficul decision facing urologists daily i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Improving Asthma Control through mHealth-Based Home Monitoring

    SBC: MAD POW MEDIA SOLUTIONS, LLC            Topic: NIMHD

    DESCRIPTION (provided by applicant): Disadvantaged, urban, and minority children incur a disproportionate share of asthma prevalence and morbidity. Interventions have been shown to improve underrepresented minority (URM) youths' adherence to NIH asthma care guidelines (e.g., proper use of long-term control medication) thereby reducing asthma morbidity. One particularly promising method of int ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Smart Sensing Dental Drill

    SBC: RYTEK MEDICAL INC            Topic: NIDCR

    DESCRIPTION provided by applicant Clinical Importance Almost million dental implants were placed worldwide in with million of these procedures taking place in the United States The worldwide market for these implants is expected to increase to $ $ billion in revenue by as dental implant manufactures target and train general dentists non surgically trained to perform th ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. A Low Cost, Quantitative, Chemical Specific Device for Illicit Drug Detection

    SBC: MKS Technology            Topic: NIDA

    DESCRIPTION provided by applicant This proposal will assess the quantitative capabilities of surface enhanced Raman scattering SERS detection of cocaine and marijuana metabolites in urine samples Combining low cost instrumentation and novel chemical sensing provides an innovative new approach for diagnosing illicit drug use Current methods use a colorimetric indicator to screen specimens fo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease

    SBC: Immunext, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Systemic lupus erythematosus SLE is a devastating autoimmune disease that most commonly affects women in their child bearing years SLE attacks multiple organ systems but renal and neurologic involvement are the usual harbingers of poor outcome Despite effective albeit toxic immunosuppressive therapy only of patients with these serious manifestations ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Design and Development of Immunotolerant S. aureus Biotherapies

    SBC: STEALTH BIOLOGICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant Antibiotic resistance complicates the majority of Staphylococcus aureus S aureus infections as a full two thirds of hospital associated S aureus infections and of those acquired in the community are now methicillin resistant MRSA MRSA causes andgt infections in the US each year and it is responsible for half of all deaths caused by drug re ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Bioimpedance based Intracranial Mapping for Monitoring Evolving TBI

    SBC: RYTEK MEDICAL INC            Topic: 105

    ABSTRACT Approximately million individuals suffer from traumatic brain injury TBI annually with over expected to die as a result of their injury In these most severe cases patients are typically admitted to the intensive care unit ICU for continuous monitoring and treatment of their injury Standard monitoring includes implantation of an intracranial pressure ICP sensor arterial ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Design and Development of Immunotolerant S. aureus Biotherapies

    SBC: Lyticon LLC            Topic: R

    The increasing incidence of multi drug resistance in Staphylococcus aureus and other bacteria represents a public health crisisTwo thirds of hospital associated Saureus infections andof those acquired in the community are now methicillin resistantMRSAMRSA causes rtinfections in the US each yearand it is responsible for half of all US deaths caused by drug resistant bacteriaThis threat to public he ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Inhibitors of PSMB and PSMB for the Treatment of Multiple Myeloma

    SBC: InhiProt            Topic: 103

    Multiple myeloma is incurable hematologic malignancy with an expected median survival of years The proteasome inhibitors bortezomib carfilzomib and the recently approved ixazomib are a mainstay of current myeloma treatment Despite an initial response rate approaching to proteasome inhibitor containing combinations all patients relapse and eventually become resistant to any treatments ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government